JP2020196709A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020196709A5 JP2020196709A5 JP2020093919A JP2020093919A JP2020196709A5 JP 2020196709 A5 JP2020196709 A5 JP 2020196709A5 JP 2020093919 A JP2020093919 A JP 2020093919A JP 2020093919 A JP2020093919 A JP 2020093919A JP 2020196709 A5 JP2020196709 A5 JP 2020196709A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- disorder
- formula
- alkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005843 halogen group Chemical group 0.000 claims 59
- 125000000217 alkyl group Chemical group 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000003545 alkoxy group Chemical group 0.000 claims 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 25
- 125000001424 substituent group Chemical group 0.000 claims 24
- 208000035475 disorder Diseases 0.000 claims 20
- 208000020401 Depressive disease Diseases 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 125000002837 carbocyclic group Chemical group 0.000 claims 16
- 102000005962 receptors Human genes 0.000 claims 14
- 108020003175 receptors Proteins 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 13
- -1 cyano, hydroxy Chemical group 0.000 claims 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 208000019901 Anxiety disease Diseases 0.000 claims 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 9
- 208000020925 Bipolar disease Diseases 0.000 claims 9
- 206010012289 Dementia Diseases 0.000 claims 9
- 208000008589 Obesity Diseases 0.000 claims 9
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 9
- 206010044565 Tremor Diseases 0.000 claims 9
- 208000010877 cognitive disease Diseases 0.000 claims 9
- 206010013663 drug dependence Diseases 0.000 claims 9
- 235000020824 obesity Nutrition 0.000 claims 9
- 208000019116 sleep disease Diseases 0.000 claims 9
- 208000011117 substance-related disease Diseases 0.000 claims 9
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 8
- 208000027520 Somatoform disease Diseases 0.000 claims 8
- 208000029560 autism spectrum disease Diseases 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 208000027753 pain disease Diseases 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 8
- 230000000069 prophylactic effect Effects 0.000 claims 8
- 201000000980 schizophrenia Diseases 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 208000005392 Spasm Diseases 0.000 claims 7
- 208000026345 acute stress disease Diseases 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 229940127557 pharmaceutical product Drugs 0.000 claims 6
- 208000020016 psychiatric disease Diseases 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003054 catalyst Substances 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229910052723 transition metal Inorganic materials 0.000 claims 4
- 150000003624 transition metals Chemical class 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000007363 ring formation reaction Methods 0.000 claims 3
- 208000020685 sleep-wake disease Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- VPKVKBZXORVFIU-UHFFFAOYSA-N 1-fluoroimidazole Chemical compound FN1C=CN=C1 VPKVKBZXORVFIU-UHFFFAOYSA-N 0.000 claims 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 238000006751 Mitsunobu reaction Methods 0.000 claims 2
- 208000007101 Muscle Cramp Diseases 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 2
- 125000005620 boronic acid group Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- IWDFHWZHHOSSGR-UHFFFAOYSA-N 1-ethylimidazole Chemical compound CCN1C=CN=C1 IWDFHWZHHOSSGR-UHFFFAOYSA-N 0.000 claims 1
- IYVYLVCVXXCYRI-UHFFFAOYSA-N 1-propylimidazole Chemical compound CCCN1C=CN=C1 IYVYLVCVXXCYRI-UHFFFAOYSA-N 0.000 claims 1
- SBPIDKODQVLBGV-UHFFFAOYSA-N 1h-imidazole;pyridine Chemical compound C1=CNC=N1.C1=CC=NC=C1 SBPIDKODQVLBGV-UHFFFAOYSA-N 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000002140 halogenating effect Effects 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- MXZANEWAFZMPKW-UHFFFAOYSA-N imidazol-1-amine Chemical compound NN1C=CN=C1 MXZANEWAFZMPKW-UHFFFAOYSA-N 0.000 claims 1
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- VNQRMCDTTYOMKZ-YFKPBYRVSA-N C[C@@H](CN1)N2NCC=C2C1=O Chemical compound C[C@@H](CN1)N2NCC=C2C1=O VNQRMCDTTYOMKZ-YFKPBYRVSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023066929A JP7550913B2 (ja) | 2019-05-30 | 2023-04-17 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体又はその塩を含有する医薬 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019101008 | 2019-05-30 | ||
| JP2019101008 | 2019-05-30 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023066929A Division JP7550913B2 (ja) | 2019-05-30 | 2023-04-17 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体又はその塩を含有する医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020196709A JP2020196709A (ja) | 2020-12-10 |
| JP2020196709A5 true JP2020196709A5 (enrdf_load_stackoverflow) | 2022-01-06 |
| JP7266010B2 JP7266010B2 (ja) | 2023-04-27 |
Family
ID=73648827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020093919A Active JP7266010B2 (ja) | 2019-05-30 | 2020-05-29 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体又はその塩を含有する医薬 |
| JP2023066929A Active JP7550913B2 (ja) | 2019-05-30 | 2023-04-17 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体又はその塩を含有する医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023066929A Active JP7550913B2 (ja) | 2019-05-30 | 2023-04-17 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体又はその塩を含有する医薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP7266010B2 (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7242548B2 (ja) * | 2017-11-24 | 2023-03-20 | 住友ファーマ株式会社 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2704436C (en) * | 2007-11-14 | 2016-01-05 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2010060589A1 (en) * | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| JO3368B1 (ar) * | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| ES2707525T3 (es) * | 2014-08-01 | 2019-04-03 | Janssen Pharmaceutica Nv | Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5H)-ona y su uso como moduladores alostéricos negativos de receptores de mGlu2 |
| RU2711382C2 (ru) * | 2014-12-03 | 2020-01-16 | Янссен Фармацевтика Нв | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 |
| JP2018154554A (ja) * | 2015-07-29 | 2018-10-04 | 大日本住友製薬株式会社 | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 |
| JP7242548B2 (ja) * | 2017-11-24 | 2023-03-20 | 住友ファーマ株式会社 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途 |
| JP2019182784A (ja) * | 2018-04-10 | 2019-10-24 | 大日本住友製薬株式会社 | ジヒドロピラゾロピラジノン誘導体 |
| JP2020193176A (ja) * | 2019-05-30 | 2020-12-03 | 大日本住友製薬株式会社 | 新規ビアリール誘導体及びその医薬用途 |
-
2020
- 2020-05-29 JP JP2020093919A patent/JP7266010B2/ja active Active
-
2023
- 2023-04-17 JP JP2023066929A patent/JP7550913B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6063870B2 (ja) | ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 | |
| JP5789288B2 (ja) | 可溶性グアニル酸シクラーゼアクチベーター | |
| JP7094989B2 (ja) | シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト | |
| JP4132666B2 (ja) | 含窒素複素環誘導体およびその医薬 | |
| JP5501369B2 (ja) | 可溶性グアニレートシクラーゼ活性化剤 | |
| JP6826116B2 (ja) | プラスメプシンｖ阻害薬としてのイミノテトラヒドロピリミジノン誘導体 | |
| JP6346658B2 (ja) | Ｍａｏ阻害剤としての置換ナフチリジン及びキノリン化合物 | |
| JP6505023B2 (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| TWI691490B (zh) | 四氫喹啉衍生物的合成中間體、製備方法及用途 | |
| US5475008A (en) | Quinolone derivatives | |
| JP2012501327A5 (enrdf_load_stackoverflow) | ||
| EA002607B1 (ru) | Замещенные 6,6-гетеро-бициклические производные | |
| KR20010050223A (ko) | Ｃｒｆ 길항제 및 관련 조성물의 용도 | |
| US20070043074A1 (en) | Imidazo[1,2-a] pyridine anxiolytics | |
| JP2012509877A5 (enrdf_load_stackoverflow) | ||
| EP2807164A1 (en) | Imidazopyrrolidinone compounds | |
| RU2016141647A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2013519724A5 (enrdf_load_stackoverflow) | ||
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| JP6953527B2 (ja) | 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用 | |
| AU2018373464A1 (en) | 6,7-dihydropyrazolo[1,5-a] pyrazinone derivative and medical use thereof | |
| WO2002068419A1 (fr) | Derive de pyridopyrimidine ou naphthyridine | |
| JP2020196709A5 (enrdf_load_stackoverflow) | ||
| EP1575960B1 (fr) | Derives de 1,4-diazabicyclo¬3.2.2 nonanecarboxamides, leur preparation et leur application en therapeutique ayant trait au dysfonctionnement des recepteurs nicotiniques | |
| JP2020193176A (ja) | 新規ビアリール誘導体及びその医薬用途 |